Clinical trial · no report yet · Phase 3
INAVO123
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- NCT06790693 ↗
- Recruiting
- Hoffmann-La Roche
- 12 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 7 | |
| YouTube | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Breast Cancer
- Interventions
- Inavolisib; Placebo; CDK4/6i; Letrozole
- Arms
- Inavolisib + Letrozole + CDK4/6i · Experimental
- Placebo + Letrozole + CDK4/6i · Placebo comparator
- Enrollment
- 450 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS)
- Sponsor
- Hoffmann-La Roche
- Start
- Apr 9, 2025
- Primary completion
- Jan 31, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT06790693 · updated Oct 6, 2026